Ferroportin inhibitors

US11066399B2 · kind B2 · utility

Assignee

• Vifor (International) AG · CH

Inventors

• Franz Dürrenberger · Dornach, CH
• Michael Burgert · Friedrichshafen, DE
• Susanna Burckhardt · Zürich, CH
• Wilm Buhr · Konstanz, DE
• Aris Kalogerakis · Winterthur, CH
• Stefan Reim · Sankt Gallen, CH
• Vania Manolova · Zollikon, CH
• Susan Boyce · Quickborn, DE
• Christopher John Yarnold · Shrewsbury, GB
• Paula Pena · Witney, GB
• Jon Shepherd · Abingdon, GB
• Cristina Lecci · Abingdon, GB
• Richard Jarjes-Pike · Newbury, GB
• John Scott · Abingdon, GB

Key dates

• Filing date: Dec 3, 2020
• Grant date: Jul 20, 2021
• Expiry date: Dec 3, 2040

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.